MedTrace Logo

Interest of the S100B Protein Assay in Mild Traumatic Brain Injuries at the DOUAI Hospital

NCT05285774 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2023-08-30

No results posted yet for this study

Summary

The main objective is to evaluate the feasibility and interest of setting up a protocol for the systematic measurement of the S100B protein in patients with mild traumatic brain injury admitted to the emergency room of Douai hospital in order to reduce the number of unnecessary brain scans. The main evaluation criterion is the percentage of patients admitted to the emergency department of Douai hospital for mild traumatic brain injury, whose protocol for the systematic measurement of the S100B protein would make it possible to avoid the realization of a brain scans for patients with a protein assay S100B ≤ 0.10 µg/L, carried out within 3h of the onset of MCT.

The systematic dosage of the S100B protein in the context of mild traumatic brain injury still does not appear in the recommendations for good practice in 2021. This study will contribute to the reflection on the use of the S100B protein in the development of new recommendations for good practice of mild traumatic brain injury support.

Conditions

  • Mild Brain Traumatic Injury
  • Compliance, Patient

Sponsors & Collaborators

  • Centre Hospitalier de Douai

    lead OTHER

Principal Investigators

  • Justine HERENG · Centre Hospitalier de Douai

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-06
Primary Completion
2023-08-06
Completion
2023-08-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05285774 on ClinicalTrials.gov